malignant ascites pipeline insight

DelveInsight’s, “Malignant Ascites Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Malignant Ascites pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Malignant Ascites Understanding

Malignant Ascites Overview

Malignant ascites is a cancer-related condition characterized by the abnormal accumulation of fluid within the abdominal cavity, most commonly occurring in advanced malignancies involving the peritoneum or liver and is generally associated with poor clinical outcomes. The condition develops due to a combination of increased vascular permeability and impaired lymphatic drainage caused by tumor progression. 

It is frequently observed in cancers such as ovarian, colorectal, gastric, pancreatic, breast, and mesothelial malignancies, and in some cases may serve as an initial sign of peritoneal carcinomatosis. Patients commonly present with progressive abdominal swelling, bloating, pain, and a noticeable increase in abdominal girth. As fluid accumulation worsens, symptoms such as shortness of breath, nausea, vomiting, early satiety, fatigue, reduced appetite, constipation, impaired mobility, and lower-limb edema may significantly impact quality of life. 

The development of malignant ascites is driven by tumor-mediated fluid accumulation resulting from increased vascular permeability, commonly associated with vascular endothelial growth factor (VEGF), along with compromised lymphatic drainage. Peritoneal dissemination of tumor cells and portal hypertension related to hepatic involvement further contribute to excessive fluid buildup within the abdominal cavity. In addition to being a clinical manifestation, ascitic fluid also functions as a biologically active tumor microenvironment that promotes inflammation, angiogenesis, and ongoing disease progression.

Diagnosis of malignant ascites primarily relies on diagnostic paracentesis with ascitic fluid analysis, as imaging and physical examination alone cannot reliably confirm malignancy. Evaluation typically includes albumin and protein levels, cell count, cytology, and calculation of the serum-ascites albumin gradient (SAAG). Cytological detection of malignant cells remains the gold standard, while tumor markers and, when needed, laparoscopy or peritoneal biopsy may help identify the underlying malignancy.
Management of malignant ascites is mainly palliative and aimed at symptom relief, with paracentesis being the most effective and commonly used intervention for rapid fluid removal. Diuretics may provide limited benefit in selected patients, although repeated drainage is often required due to fluid recurrence. In recurrent cases, indwelling catheters or shunts may improve quality of life, while systemic, intraperitoneal, or targeted anticancer therapies may help reduce further fluid accumulation in suitable patients.

"Malignant Ascites Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant Ascites pipeline landscape is provided which includes the disease overview and Malignant Ascites treatment guidelines. The assessment part of the report embraces, in depth Malignant Ascites commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant Ascites collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Malignant Ascites Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Malignant Ascites R&D. The therapies under development are focused on novel approaches to treat/improve Malignant Ascites.

Malignant Ascites Emerging Drugs Analysis

This segment of the Malignant Ascites report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malignant Ascites Emerging Drugs

M701: YZY Biopharma

M701 is a first-in-class biologic developed by YZY Biopharma using its proprietary YBODY® asymmetric bispecific antibody platform. The therapy simultaneously targets EpCAM and CD3 to redirect and activate T cells against EpCAM-positive tumor cells. It is being developed for the treatment of malignant ascites and malignant pleural effusion associated with EpCAM-expressing cancers, and is currently undergoing Phase III clinical evaluation for malignant ascites.

Further product details are provided in the report……..

Malignant Ascites Drug Therapeutic Assessment

This segment of the report provides insights about the different Malignant Ascites drugs segregated based on following parameters that define the scope of the report, such as:

Major Malignant Ascites Players in Malignant Ascites

There are approx. 3+ key companies which are developing the therapies for Malignant Ascites. The companies which have their Malignant Ascites drug candidates in the most advanced stage, i.e. Phase III include, YZY Biopharma.

Malignant Ascites Clinical Trial Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Malignant Ascites Drug Route of Administration

Malignant Ascites pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Malignant Ascites Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Malignant Ascites Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malignant Ascites Clinical Trial Activities

The Malignant Ascites Pipeline report provides insights into different Malignant Ascites Clinical Trial within Phase III, II, I, preclinical and discovery stage. It also analyses Malignant Ascites therapeutic drugs key players involved in developing key drugs. 

Malignant Ascites Pipeline Development Activities

The Malignant Ascites Clinical Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant Ascites drugs.

Malignant Ascites Pipeline Report Insights

• Malignant Ascites Pipeline Analysis
• Malignant Ascites Therapeutic Assessment
• Malignant Ascites Unmet Needs
• Impact of Malignant Ascites Drugs

Malignant Ascites Report Assessment

• Malignant Ascites Pipeline Product Profiles
• Malignant Ascites Therapeutic Assessment
• Malignant Ascites Pipeline Assessment
• Malignant Ascites Inactive drugs assessment
• Malignant Ascites Market Unmet Needs

Key Questions Answered In the Malignant Ascites Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Malignant Ascites drugs?
• How many Malignant Ascites drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant Ascites?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Malignant Ascites therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Malignant Ascites and their status?
• What are the key designations that have been granted to the emerging drugs?

Malignant Ascites Key Players

• YZY Biopharma
• Jiangsu Simcere Pharmaceutical Co., Ltd.

Malignant Ascites Key Products

• M701
• SIM0388